Literature DB >> 12871125

Hexokinase II: the integration of energy metabolism and control of apoptosis.

John G Pastorino1, Jan B Hoek.   

Abstract

Hexokinase II is often highly expressed in poorly differentiated and rapidly growing tumors that exhibit a high rate of aerobic glycolysis. Hexokinase II binds to the mitochondrial membrane through its interaction with the outer membrane voltage-dependent anion channel (VDAC), preferentially at contact sites between the outer and inner mitochondrial membrane. This location is thought to be important for the integration of glycolysis with mitochondrial energy metabolism. VDAC is a critical component of the mitochondrial phase of apoptosis and its interaction with Bcl-2 family proteins controls the rate of release of mitochondrial intermembrane space proteins that activate the execution phase of apoptosis. The proteins involved in the contact sites also constitute the mitochondrial permeability transition, one of the mechanisms by which mitochondrial protein release can be mediated. Hexokinase II binding to VDAC suppresses the release of intermembrane space proteins and inhibits apoptosis, thereby contributing to the survival advantage of tumor cells. This interaction places hexokinase II in a position to integrate glycolytic metabolism of the tumor cell with the control of apoptosis at the mitochondrial level. Mitochondrial binding of hexokinase II may constitute an attractive target for therapeutic intervention to suppress tumor growth.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871125     DOI: 10.2174/0929867033457269

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  94 in total

1.  FDG PET in Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  PET Clin       Date:  2009-04-01

2.  Voltage dependent anion channel-1 (VDAC-1) as an anti-cancer target.

Authors:  Saroj P Mathupala; Peter L Pedersen
Journal:  Cancer Biol Ther       Date:  2010-06-21       Impact factor: 4.742

3.  Reduction in hexokinase II levels results in decreased cardiac function and altered remodeling after ischemia/reperfusion injury.

Authors:  Rongxue Wu; Kirsten M Smeele; Eugene Wyatt; Yoshihiko Ichikawa; Otto Eerbeek; Lin Sun; Kusum Chawla; Markus W Hollmann; Varun Nagpal; Sami Heikkinen; Markku Laakso; Kentaro Jujo; J Andrew Wasserstrom; Coert J Zuurbier; Hossein Ardehali
Journal:  Circ Res       Date:  2010-11-11       Impact factor: 17.367

4.  Clotrimazole induces a late G1 cell cycle arrest and sensitizes glioblastoma cells to radiation in vitro.

Authors:  Hui Liu; Yufeng Li; Kevin P Raisch
Journal:  Anticancer Drugs       Date:  2010-10       Impact factor: 2.248

5.  On the role of VDAC in apoptosis: fact and fiction.

Authors:  Tatiana K Rostovtseva; Wenzhi Tan; Marco Colombini
Journal:  J Bioenerg Biomembr       Date:  2005-06       Impact factor: 2.945

6.  MondoA-Mlx heterodimers are candidate sensors of cellular energy status: mitochondrial localization and direct regulation of glycolysis.

Authors:  Christopher L Sans; Daniel J Satterwhite; Carrie A Stoltzman; Kevin T Breen; Donald E Ayer
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

Review 7.  Mitochondrial ion channels.

Authors:  Brian O'Rourke
Journal:  Annu Rev Physiol       Date:  2007       Impact factor: 19.318

Review 8.  VDAC Regulation: A Mitochondrial Target to Stop Cell Proliferation.

Authors:  Diana Fang; Eduardo N Maldonado
Journal:  Adv Cancer Res       Date:  2018-03-02       Impact factor: 6.242

Review 9.  Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen.

Authors:  Peter L Pedersen
Journal:  J Bioenerg Biomembr       Date:  2007-06       Impact factor: 2.945

10.  Mitochondrial VDAC and hexokinase together modulate plant programmed cell death.

Authors:  Ashwini Godbole; Ashvini Kumar Dubey; Palakolanu S Reddy; M Udayakumar; Mathew K Mathew
Journal:  Protoplasma       Date:  2012-12-18       Impact factor: 3.356

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.